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BACKGROUND: The physiology underlying "brain fog" in the absence of orthostatic stress in postural tachycardia syndrome 
(POTS) remains poorly understood.
METHODS AND RESULTS: We evaluated cognitive and hemodynamic responses (cardiovascular and cerebral: heart rate, blood 
pressure, end-tidal carbon dioxide, and cerebral blood flow velocity (CBFv) in the middle cerebral artery at baseline, after 
initial cognitive testing, and after (30-minutes duration) prolonged cognitive stress test (PCST) whilst seated; as well as after 
5-minute standing in consecutively enrolled participants with POTS (n=22) and healthy controls (n=18). Symptom severity was 
quantified with orthostatic hypotensive questionnaire at baseline and end of study. Subjects in POTS and control groups were 
frequency age- and sex-matched (29±11 versus 28±13 years; 86 versus 72% women, respectively; both P≥0.4). The CBFv 
decreased in both groups (condition, P=0.04) following PCST, but a greater reduction in CBFv was observed in the POTS ver-
sus control group (−7.8% versus −1.8%; interaction, P=0.038). Notably, the reduced CBFv following PCST in the POTS group 
was similar to that seen during orthostatic stress (60.0±14.9 versus 60.4±14.8 cm/s). Further, PCST resulted in greater slowing 
in psychomotor speed (6.1% versus 1.4%, interaction, P=0.027) and a greater increase in symptom scores at study comple-
tion (interaction, P<0.001) in the patients with POTS, including increased difficulty with concentration. All other physiologic 
responses (blood pressure and end-tidal carbon dioxide) did not differ between groups after PCST (all P>0.05).
CONCLUSIONS: Reduced CBFv and cognitive dysfunction were evident in patients with POTS following prolonged cognitive 
stress even in the absence of orthostatic stress.
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Individuals with postural tachycardia syndrome (POTS) often experience several debilitating cardiovascular, gastrointestinal, and neuropsychologic symptoms in 
addition to their intolerance to standing.1 Although it is 
clear that symptoms are related to the assumption of 
upright posture in these individuals, a myriad of fac-
tors that reduce blood volume or decrease vascular 
tone (such as hot environments, large meals, physical 
exertion, cardiac deconditioning, and medications) are 
known to exacerbate POTS symptoms and interfere 
with activities of daily living.2–5 The impact of these 
symptoms on quality of life and cognitive dysfunction 
has been well described, however, effective treatment 
options remain limited.6 Correction of dehydration, 
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exercise training, and manipulation of vasoactive and 
heart rate (HR) slowing medications may provide some 
symptomatic relief, however, improvement in therapeu-
tic approach will require a better understanding of the 
underlying heterogeneous pathophysiology.6–10
Cognitive dysfunction in patients with POTS is 
sometimes attributed to concurrent anxiety and de-
pression, although performance in tasks requiring 
sustained attention and short-term memory has also 
been shown to deteriorate with orthostatic stress.11,12 
The association of cognitive dysfunction with upright 
posture may relate to a reduction in cerebral blood 
flow (CBF) or oscillations in blood pressure (BP) and 
CBF velocity (CBFv).12,13 However, the persistence 
of mental fatigue and cognitive disturbances (“brain 
fog”) even in a recumbent position, have been re-
ported in POTS.14 It remains unclear whether these 
symptoms can be explained by abnormal cerebral 
perfusion in the absence of orthostatic stress. We 
therefore hypothesized that CBFv is reduced in pa-
tients with POTS when they are subjected to pro-
longed cognitive stress performed in the seated 
position, akin to during orthostatic stress.
METHODS
We evaluated cognitive and hemodynamic responses 
(cardiovascular and cerebral) at baseline, after initial cog-
nitive testing and after a 30-minutes duration prolonged 
cognitive stress test (PCST) whilst seated, as well as after 
orthostatic stress (5-minute standing) in consecutively 
enrolled participants with POTS (POTS group, Figure 1). 
We compared these with a cohort of frequency age- and 
sex-matched healthy participants (control group). This 
study was approved by the institutional human research 
ethics committee and conformed to the Declaration of 
Helsinki. All participants provided written, informed con-
sent before their inclusion in the study. The data that 
support the findings of this study are available from the 
corresponding author upon reasonable request.
Study Eligibility and Enrollment
Individuals with POTS were enrolled from our auto-
nomic clinic, where specific clinical criteria were met: 
symptoms produced by upright posture with resolu-
tion when recumbent for at least 6 months in duration, 
as well as documentation of a sustained increment of 
HR of >30 bpm during head-up tilt testing or within 
10 minutes of standing, without a postural BP drop of 
>20 mm Hg. These symptoms included light-headed-
ness, headache, fatigue, neurocognitive deficits, palpi-
tations, nausea, altered vision, or shortness of breath 
while upright, with no other medical explanation for 
the symptoms. All patients with POTS were on treat-
ment in accordance with current guidelines.7 There 
were no clinical exclusion criteria. The control group 
consisted of age- and sex-matched healthy volunteers 
with no known cardiac or autonomic symptoms.
Patient Preparation
All testing sessions were performed in the morning, 
with patients abstaining from alcohol and caffeine over 
the preceding 24  hours. No changes were made to 
POTS treatment in the preceding month. Participants 
were permitted to continue all their usual medications 
except for vasopressors. Patients who usually took 
midodrine (α-adrenergic agonist, half-life of 3 hours) in 
the morning were asked to delay this dose until after 
completing the study, allowing an interval of at least 
15 hours (5x half-life) to elapse from the last dose, to 
avoid exogenous vasopressor therapy confounding 
CLINICAL PERSPECTIVE
What Is New?
▪ Compared with age- and sex-matched healthy 
controls, patients with postural tachycardia 
syndrome demonstrated greater reduction in 
cerebral blood flow velocity and psychomotor 
speed following prolonged cognitive stress test-
ing even in the absence of orthostatic stress.
▪ The reduction in cerebral blood flow velocity in 
the middle cerebral artery of patients with pos-
tural tachycardia syndrome was similar during 
prolonged cognitive stress testing and after 5 
minutes of standing.
What Are the Clinical Implications?
▪ Our findings may explain the common descrip-
tion of ‘brain fog’ in patients with postural tachy-
cardia syndrome and provide further strength to 
the concept that cognitive dysfunction in pos-
tural tachycardia syndrome represents a con-
sequence of the disease pathophysiology.
▪ Further studies are needed to delineate the 
pathophysiological mechanisms underlying 
these observations.
Nonstandard Abbreviations and Acronyms
CBFv cerebral blood flow velocity
ETCO2 end-tidal carbon dioxide
HR heart rate
ICT initial cognitive test
PCST prolonged cognitive stress test
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interpretation of the study results. The study pro-
tocol was performed in a climate-controlled facility 
(22°C), with participants seated with back support at 
a desk, emulating normal (school or clerical) working 
conditions.
Physiological Measurements
We used transcranial Doppler (TCD) to measure 
CBFv from the middle cerebral artery of the dominant 
hemisphere (Doppler-BoxX, Compumedics DWL, 
Singen, Germany). A 2-MHz transducer probe (PW, 
Compumedics DWL) was fixed in place over the tran-
stemporal window using adjustable headgear (DiaMon, 
Compumedics DWL) to minimize movement of the probe 
during the study protocol. CBFv was recorded continu-
ously throughout the study protocol. A single-lead ECG 
(FE132 Bioamp, ADInstruments Pty Ltd, NSW, Australia) 
was placed for continuous monitoring. Continuous, non-
invasive beat-to-beat hemodynamics (HR, BP) were also 
obtained using a cuff placed on the finger (photoplethys-
mography; Finapres Medical Systems BV, Enschede, 
The Netherlands). A chest wall strain gauge (MLT 1132/D 
Piezo Respiratory Belt Transducer, ADInstruments) was 
used to measure respiratory rate. Lastly, end-tidal car-
bon dioxide (ETCO2) was measured (Capnostream 20P, 
Medtronic, Minneapolis, MN, USA) via nasal prongs with 
mouth scoop (Smart CapnoLine Plus, Microstream, 
Medtronic). The CBFv wave envelope, ECG, beat-to-
beat BP waveform and HR, ETCO2, and respiratory rate 
data were all recorded simultaneously through a data 
acquisition device (Powerlab PL35/16, ADInstruments) 
connected to a personal computer using data acquisi-
tion software (LabChart 8, ADInstruments). All data were 
exported to MATLAB (MathWorks, Natick, MA, USA) for 
further analysis.
Neurocognitive Assessment
We performed cognitive testing using an iPad-based 
(Apple Inc., Cupertino, CA, USA) software collection 
tool (Cambridge Neuropsychological Test Automated 
Battery [CANTAB]; Cambridge Cognition, Cambridge, 
UK).15 Specifically, we assessed the cognitive domains 
of psychomotor speed and attention by measuring re-
action time (RT) and rapid visual information process-
ing, respectively. In brief, the RT test measures the 
time taken to release an on-screen button and touch 
a target in response to a programmed visual stimulus. 
It measures the speed of both motor and mental re-
sponse. The rapid visual information processing task 
assesses the subject’s ability to identify a target se-
quence from a series of numbers that flash up in a 
pseudo random order onto the iPad screen at a rate of 
Figure 1. Study schema.
Sequence of physiologic and cognitive measurements during the entire study protocol. RT indicates reaction time; RVIP, rapid visual 
information processing; OHQ, orthostatic hypotension questionnaire; COMPASS-31, composite autonomic symptom score-31; and 
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100 numbers per minute as a measure of sustained at-
tention. Both RT and rapid visual information process-
ing were measured at baseline and after 30 minutes of 
PCST (Figure 1). The 2 Cambridge Neuropsychological 
Test Automated Battery tasks used to produce cog-
nitive stress were: delayed matched samples task, 
which involves recall of complex patterns, and atten-
tion switching task, which requires a motor response 
to rapid visual changes in the position and direction of 
an arrow that appears on the screen.
Symptom Assessment
To assess acute changes in symptoms we asked par-
ticipants to rate their symptoms using the Orthostatic 
Hypotension Questionnaire with the Likert scale (from 
0–10; least to most severe), at baseline and after the 
prolonged cognitive stress testing.16 The symptoms 
assessed were: dizziness, light-headedness or feeling 
faint; problems with vision (blurring, seeing spots, tun-
nel vision); weakness; fatigue; trouble concentrating; 
and head and neck discomfort. While the orthostatic 
hypotension questionnaire refers to symptoms experi-
enced over the preceding week, we adapted it to as-
sess immediate symptoms.
In addition to assessing current symptoms, all par-
ticipants were also asked to complete questionnaires 
at completion of all physiologic measurements to de-
termine their quality of life and autonomic symptoms in 
the preceding month. A questionnaire to assess quality 
of life specifically in POTS is not available. The Quality 
of Life Assessment in Multiple System Atrophy ques-
tionnaire was used to assess quality of life, which has 
been well validated as a patient-reported outcomes 
tool.17 Further, autonomic symptoms were assessed 
using the well validated, abbreviated composite auto-
nomic symptom score-31).18
Statistical Analysis
Normally distributed variables were presented as 
mean±SD while non-normally distributed variables 
were presented as median and interquartile range (Q1, 
Q3). Categorical variables were expressed as numbers 
and percentages. We used averaged physiologic data 
over 30 s at the following time points for comparison: 
at baseline whilst seated, whilst undertaking the initial 
cognitive testing (ICT) and undertaking repeat cogni-
tive testing after 30  minutes of PCST whilst seated, 
and during the 5-minute stand test. A mixed effects 
model was used to assess group (POTS, controls) and 
condition (baseline versus ICT, ICT versus post PCST, 
baseline versus orthostatic stress) as main effects and 
the interaction between group and condition. Individual 
patient was modeled as random effect to account for 
repeated measures within individuals between the 
conditions. Model residuals were visually inspected for 
normality to ensure an appropriate model fit. Statistical 
tests were performed using SPSS Statistics (version 
24, IBM Corp, Armonk, NY, USA) and statistical signifi-
cance was set at P<0.05.
RESULTS
Baseline characteristics
We enrolled 40 participants with POTS (n=22) and 
healthy sex- and age-matched controls (n=18). Baseline 
characteristics such as medication usage, seated physi-
ologic and CBF parameters are presented in Table 1. Of 
the 22 patients with POTS, 6 were taking fludrocortisone, 
12 were taking HR control medications (5, ivabradine; 7, 
propranolol) and 11 were taking midodrine. Notably, the 
POTS group had higher resting HR whilst seated than the 
controls (90±14 versus 74±9 bpm; P=0.010). There was 
no difference in mean resting BP, respiratory rate, ETCO2, 
and CBFv between the groups whilst seated (Table 1).
Physiologic Changes With Initial Cognitive 
Testing
There was a greater increase in mean HR in the POTS 
group than controls during ICT (9.5 versus 4.4%; inter-
action, P=0.014; Figure 2A). Mean HR was consistently 
higher in the POTS group (group, P=0.003) although 
a significant increase was seen in both groups (con-
dition, P<0.001). All other physiologic responses (BP, 
ETCO2, and CBFv) did not differ between groups 
during ICT (interaction, P values all ≥0.2, Table 2) de-
spite significant increases in systolic and diastolic BP 
(condition, P<0.001) and CBFv (condition, P=0.006) in 
both groups (Figure 2B through 2D).
Physiologic and Cognitive Changes 
During Repeat Cognitive Testing After 
PCST
HR response during repeat cognitive testing after PCST 
was similar between groups (interaction, P=0.656, 
Table 2) with consistent slowing as compared with dur-
ing ICT (condition, P=0.042), although the POTS group 
maintained higher HR than control group throughout 
(group, P=0.005, Figure 2A). Following PCST, a greater 
reduction in CBFv was seen in the POTS group than 
controls (−7.8% versus −1.8%; interaction, P=0.038, 
Table 2 and Figure 2C), although CBFv was lower in 
both groups on repeat cognitive testing (condition, 
P<0.001). All other physiologic responses (BP and 
ETCO2) did not differ between groups during initial 
and repeat cognitive testing after PCST (all interaction, 
P≥0.061, Table 2, Figure 2B and 2D).
The effects of PCST on psychomotor speed and at-
tention are summarized in Table 2. When repeated cog-
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delay in mean RT was seen in the POTS group than con-
trols (6.1% versus 1.4%; interaction, P=0.027; Figure 2E). 
While a significant increase in mean RT was seen in 
both groups (condition, P=0.002), mean RT was consis-
tently longer in the patients with POTS (group, P=0.007, 
Figure 2E). When cognitive testing was repeated after 
PCST, the increase in the number of correct responses 
in the rapid visual information processing test did not dif-
fer between the POTS and control groups (interaction, 
P=0.108, Table 2) despite significant increase in both 
groups (condition, P<0.001; Figure 2F) and consistently 
lower accuracy in the POTS group (group, P=0.05).
Physiologic Changes at End of 5-Minute 
Orthostatic Stress
The extent of changes in all physiologic parameters (HR, 
BP, ETCO2, and CBFv) did not differ between groups 
from baseline to the end of 5-minute orthostatic stress 
(interaction P≥0.5, Table 2). Orthostatic stress resulted 
in significant increases in HR (condition, P<0.001), sys-
tolic BP (condition, P=0.001) and diastolic BP (condi-
tion, P<0.001) as well as a significant decrease in CBFv 
(condition, P=0.002) in both groups (Figure 3A through 
3D). Notably, HR was consistently higher in patients 
with POTS (group, P=0.002; Figure 3A) while the re-
maining physiologic parameters were similar between 
POTS and control groups (group, P≥0.3).
Symptom and Quality of Life 
Assessments
Overall quality of life scores (Quality of Life 
Assessment in Multiple System Atrophy) and symp-
tom scores (composite autonomic symptom score-
31) were significantly higher in the POTS group 
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Physiologic measurements (at rest and seated)
Heart rate, bpm 90±14 74±9 0.010
Systolic BP, mm Hg 112±12 110± 9 0.601
Diastolic BP, mm Hg 78± 12 78±10 0.898




ETCO2, mm Hg 35±4 36±3 0.380
CBFv, cm/s 63.0±13.9 65.3±13.3 0.758
Quality of life and symptom scores





















Data are presented as mean±SD or median (Q1, Q3). Orthostatic hypotension symptom assessment is the symptom assessment component of the orthostatic 
hypotension questionnaire used to quantify symptoms present at the time the questionnaire was completed.13 Six symptoms are given a score from 0 (symptom 
not present) to 10 (most severe), with a maximum total score of 60. The composite autonomic symptom score-31 (adjusted) is a validated score calculated from 
the raw composite autonomic symptom score-31 after applying a weighting that considers the number of points and relative importance of organ systems to the 
assessment of autonomic dysfunction.15 A high score indicates greater severity of symptoms related to autonomic dysfunction. The Quality of Life Assessment 
in Multiple System Atrophy score assesses factors that impact quality of life with a high score indicating significant impairment in quality of life.14 BP, blood 
pressure; CBFv, cerebral blood flow velocity; COMPASS-31, composite autonomic symptom score-31; ETCO2, end-tidal carbon dioxide; MSA-QoL, Quality of 
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in comparison with the control group (Table 1). All 
patients with POTS described significant symptom 
burden over at least 6 months with impaired qual-
ity of life in motor, non-motor, and emotional compo-
nents. Specifically, all patients with POTS described 
slowness of thinking and difficulty with concentra-
tion per the Quality of Life Assessment in Multiple 
System Atrophy questionnaire, with slight, moderate, 
marked, and extreme difficulty described by 3, 4, 9, 
and 6 subjects, respectively. In contrast, 12 controls 
described no difficulty concentrating, while the re-
maining 6 indicated slight difficulty. At baseline, or-
thostatic hypotensive symptoms were significantly 
higher in the POTS versus control groups (P<0.001, 
Table 1). The POTS group demonstrated consistently 
worse orthostatic symptoms (P<0.001) with a signifi-
cant increase in OHSA scores at the end of the entire 
research protocol in both groups (P<0.001) although 
the extent of increase was greater in the POTS group 
[median, 35 (31, 42) versus 3 (1, 8) or +16 versus +3 
points, P<0.001]. Specifically, following PCST and 
orthostatic stress test, all but 2 of the patients with 
POTS rated worsening symptom of “trouble concen-
trating” with a median increase of 3 (1, 4) points on 
the Likert scale. In contrast, only 9 of 18 control sub-
jects reported increased symptom of “trouble con-
centrating” with a median increase of only 0 (0, 2) 
points (P<0.001).
DISCUSSION
To our knowledge, this study is the first to evaluate 
CBFv in individuals with POTS undergoing sustained 
cognitive challenge whilst seated. We found that fol-
lowing PCST, individuals with POTS demonstrate 
cognitive dysfunction of reduced psychomotor speed 
which was accompanied by a significant reduction 
in CBFv when compared with healthy controls whilst 
remaining seated in the absence of hyperventila-
tion.19 Additionally, we found that both groups dem-
onstrated similar reductions in CBFv and increments 
in HR following orthostatic stress of 5 minutes du-
ration. Interestingly, the CBFv following PCST in the 
POTS group was not dissimilar to that seen during 
orthostatic stress. In addition, a greater increase in 
orthostatic symptoms were reported by the patients 
with POTS as compared with healthy controls at the 
completion of the entire study protocol. Taken to-
gether, the decline in CBFv in seated individuals with 
POTS during repeat cognitive testing following PCST 
may explain the common symptom of mental cloud-
ing (brain fog) in this patient population.
CBF and Cognition in POTS
Systemic BP and HR can vary enormously during periods 
of physical stress and orthostasis. It has been postulated 
that patients with POTS are unable to adequately buffer 
Figure 2. Physiologic and cognitive parameters with cognitive challenges.
Changes in (A) heart rate; (B) systolic blood pressure; (C) cerebral blood flow velocity; (D) end-tidal carbon dioxide; (E) reaction time, 
and (F) number of correct responses with rapid visual information processing, with initial cognitive test and prolonged cognitive 
stress test are illustrated with the P values in each graph denoting comparisons for: *condition (baseline vs initial cognitive test or 
initial cognitive test vs post prolonged cognitive stress test) in both groups, †group (postural tachycardia syndrome vs control), and 
‡interaction (between condition and group). For ease of illustration, all values plotted are mean±SE of the mean with unidirectional 
error bars. POTS indicates postural tachycardia syndrome; ICT, initial cognitive test; PCST, prolonged cognitive stress test; and RVIP, 
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changes in the systemic circulation without compromis-
ing cerebral perfusion, termed autoregulation.20 Several 
studies have evaluated the effect of orthostatic stress on 
cognitive function and cerebral hemodynamics in patients 
with POTS. Ocon et al found a decline in cognitive perfor-
mance occurring with increasing orthostatic stress in pa-
tients with POTS and comorbid chronic fatigue syndrome 
as compared with controls, that could not be explained 
by reduced CBFv.21 In patients with chronic fatigue syn-
drome and POTS, Stewart et al found that CBF failed to 
increase with cognitive activity during orthostatic stress 
while vasomotor tone remained elevated, suggesting an 
uncoupling of the neurovascular unit.22 During progres-
sive orthostasis in patients with POTS, increasing oscilla-
tory CBF has been shown to be associated with memory 
deterioration and reduced neurovascular coupling.12
While the above studies have elegantly highlighted 
the complexities of cerebral hemodynamic response 
during orthostatic stress in relationship with cognitive 
function in individuals with POTS, the extent to which 
these findings could be attributable to co-existing 
chronic fatigue syndrome is not known.23 Further, it 
remains unclear whether patients with POTS have the 
capacity to increase cerebral perfusion in response to 
increased cerebral metabolic demand in the absence of 
orthostatic stress. Others have shown that individuals 
with POTS encounter cognitive difficulties even when 
recumbent.14 In a recent study, we found both short-
term memory and alertness were impaired in patients 
with POTS whilst seated, despite demonstrating similar 
CBFv response to transient visual stimuli in the posterior 
cerebral artery when compared with healthy controls.24 
The current study provides additional insights towards 
cognitive dysfunction in the POTS population. Our find-
ings suggest that in response to sustained cognitive 
demand, patients with POTS demonstrate reduction in 
CBFv to a similar degree as during orthostatic stress.
Furthermore, these changes in CBFv during PCST 
in the POTS group were seen in conjunction with re-
duced psychomotor speed and subsequent increase 
in orthostatic symptom severity including increased dif-
ficulty with concentrating, a key descriptor of brain fog, 
as compared with heathy controls. These are in keep-
ing with a previous study in which deficits in selective 
attention, cognitive processing, and executive function 
were demonstrated in patients with POTS undertaking 
Figure 3. Physiologic changes with 5-minute orthostatic stress.
Changes in (A) heart rate; (B) cerebral blood flow velocity; (C) systolic blood pressure; and (D) end-tidal carbon dioxide with orthostatic 
stress are illustrated with the P values in each graph denoting comparisons for: *condition (baseline vs orthostatic stress) in both 
groups, †group (postural tachycardia syndrome vs control) and ‡interaction (between condition and group). For ease of illustration, all 
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cognitive assessment whilst seated.14 However, the 
mechanisms underlying brain fog are likely to be multi-
factorial, as reported triggers also include lack of sleep 
and general fatigue, in the absence of orthostatic or cog-
nitive stress.25
Clinical Implications
Our findings lend further strength to the concept that 
cognitive dysfunction in POTS represents a conse-
quence of the disease pathophysiology. However, fur-
ther studies are needed to delineate the mechanisms 
underlying these observations. The use of TCD to 
measure CBF in the middle cerebral artery has been 
validated against functional magnetic resonance imag-
ing measures of flow velocities, however, TCD requires 
a high level of experience to obtain consistently high-
quality measures.26 Nevertheless, TCD measures of 
CBF may be used as an objective tool to quantitate 
physiologic states in relationship to objective cognitive 
and psychological assessments in clinical practice.27 
Whether reduced CBFv is a useful biomarker in the 
management of POTS remains to be determined.
Study Limitations
TCD measures CBFv as opposed to CBF. The meas-
ures are only equivalent if the vessel diameter does 
not vary. We did not assess middle cerebral artery 
diameter during the study, but others have previously 
observed only minor changes (<4%) in its diameter 
in response to hypocapnia and changes in BP.28 We 
measured CBFv to the dominant cerebral hemisphere. 
While there is evidence that CBF is comparable be-
tween hemispheres during orthostatic stress, CBF may 
vary between hemispheres during cognitive tasks.21,29 
Undertaking the study with participants in a supine po-
sition would have removed the degree of orthostatic 
stress associated with sitting but would have ham-
pered performance of the PCST and introduced addi-
tional noise to CBFv recordings. We acknowledge that 
our results might be impacted by allowing our patients 
with POTS to continue their medications with reduced 
sympathetic activation (in the case of beta-blockade) 
or impaired concentration (in the case of anti-anxiety 
or anti-depressant medications). However, withholding 
these agents could result in rebound tachycardia and 
impair cognitive performance through sleep depriva-
tion and mental health consequences. The usage of 
questionnaires to gauge quality of life and orthostatic 
symptoms are subjected to self-reporting bias.
CONCLUSIONS
Reduced CBFv and cognitive dysfunction were evident 
in patients with POTS following prolonged cognitive 
stress in the seated position. The commonly described 
symptom of brain fog in POTS is likely attributable to 
the underlying disease pathophysiology which remains 
poorly understood.
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